DOSEGUY

Cheque Drops

guinea pig

Also seen as: Mibolerone

The Dose Guy’s verdict
Sep 1, 2026
2 sources

This is a veterinary estrus-suppression drug for dogs. People take it in microgram doses for pre-fight or pre-lift aggression, and that is the entirety of the use case: a few minutes of heightened rage at the cost of extreme liver toxicity and zero physique benefit. There is no human data, not a single trial, case report, or pharmacokinetic study in a person. If you want competition-day aggression, halotestin delivers the same aggression and has actually been dosed in humans. I would tell a friend to skip it outright.

Would I take it?No. A dog drug with no place in a cycle.

What it is

A synthetic androgen developed by Upjohn in the 1960s for veterinary use. It was marketed to suppress estrus in female dogs. It binds the androgen receptor with high affinity and activates the progesterone receptor, which is how it suppresses estrus in dogs. It does not aromatize. It has no legitimate human formulation and never had one.

The community that uses it is tiny: competitive powerlifters and combat athletes who take a sublingual dose 30 to 60 minutes before a performance for the aggression spike. Where halotestin provides that aggression with human pharmacokinetic data behind it, cheque drops offers similar aggression at a fraction of the dose and with zero human data behind it. Nobody runs it in a cycle, nobody runs it for physique, and anyone suggesting otherwise has not used it.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The entire published literature is veterinary efficacy, veterinary toxicology, and in-vitro receptor binding. No human trial, case report, or pharmacokinetic study exists:

Mibolerone bound androgen receptors in rat tissue with high affinity and specificity, did not bind glucocorticoid receptors, and showed no appreciable binding to human sex steroid binding globulin.Endocrinology 1986 · in vitro
After 9.6 years of oral exposure, ovarian fibromas were found in 12 of 92 female dogs receiving an approximately effective dose. No such tumors occurred in 60 vehicle controls or 55 dogs given exaggerated doses.Toxicol Pathol 1985 · dog · n=207
No controlled human trial of mibolerone for efficacy, safety, dosing, or pharmacokinetics exists.as of Aug 2026

Realistic protocols

I am not writing a dosing protocol for a veterinary drug with zero human pharmacology. The community use is a microgram-scale sublingual dose, 30 to 60 minutes before competition on an empty stomach, taken once or at most a handful of times. That is not a protocol, it is a dare. Even a single use suppresses your natural testosterone production. If you do it anyway, do not repeat it, do not extend it, and get bloodwork afterward, liver enzymes especially. If aggression on competition day is what you want, halotestin at least has human dosing on record from its clinical history.

Side effects

No human safety data exists. Everything below is extrapolated from animal toxicology and community reports:

anecdotalExtreme aggression onset within 30 minutes of a sublingual dose. The intended effect, but not controllable in the way people hope.
monitorHepatotoxicity expected from the methylated structure, though no human liver data exists to quantify the risk. In dogs, chronic dosing produced ovarian tumors and virilization. There is no safe run length because there is no human data to define one.
anecdotalBlood pressure spikes and headaches reported acutely, consistent with a potent androgen taken sublingually on an empty stomach.
unknownEvery side effect in a human is unknown in the formal sense. You are the experiment, and a single-subject experiment at that.

Where to buy

No live listings from tracked vendors right now.